<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Apellis Pharmaceuticals Inc (APLS)</title>
    <description>Latest news, press releases, and SEC filings for Apellis Pharmaceuticals Inc (APLS)</description>
    <link>https://caymanjournal.com/stock/APLS</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Tue, 28 Apr 2026 04:30:13 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/APLS/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>SC14D9C — Apellis Pharmaceuticals, Inc.</title>
      <description># 🧾 What This Document Is
This is an **FAQ document** from Apellis Pharmaceuticals for its employees. It’s part of the official SEC filings related to the company&apos;s acquisition. Its purpose is to clearly explain the deal&apos;s details and directly answer the most pressing questions people inside the co</description>
      <link>https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-143698</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-143698</guid>
      <pubDate>Mon, 06 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>SC TO-C — Apellis Pharmaceuticals, Inc.</title>
      <description># 📄 What This Document Is

This is the transcript of an investor conference call held on March 31, 2026. Biogen (BIIB) executives are explaining their proposed acquisition of Apellis Pharmaceuticals (APLS). Think of it as a live Q&amp;A session where Biogen&apos;s leadership justifies the deal to Wall Stree</description>
      <link>https://caymanjournal.com/stock/APLS/sec-filing/0000950157-26-000452</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APLS/sec-filing/0000950157-26-000452</guid>
      <pubDate>Tue, 31 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>8-K — Apellis Pharmaceuticals, Inc.</title>
      <description># 🧾 What This Document Is
This is an SEC **Form 8-K filing** that announces a major deal. It includes the full, legally binding **&quot;Agreement and Plan of Merger&quot;** between Apellis Pharmaceuticals (the target) and Biogen (the buyer). In simple terms, this document is the detailed rulebook for how Bio</description>
      <link>https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-134916</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-134916</guid>
      <pubDate>Tue, 31 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>SC14D9C — Apellis Pharmaceuticals, Inc.</title>
      <description># 🧾 What This Document Is
This is an SEC filing called a **Schedule 14D-9**. Think of it as a formal &quot;Q&amp;A and Announcement&quot; document a company must file when someone is trying to buy it through a **tender offer**. It’s not the offer itself, but Apellis&apos; official response and collection of related c</description>
      <link>https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-135019</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APLS/sec-filing/0001193125-26-135019</guid>
      <pubDate>Tue, 31 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>